Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a research note published on Friday,Benzinga reports. The brokerage issued an overweight rating on the stock.

Other equities analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Acrivon Therapeutics in a report on Thursday, November 14th. KeyCorp began coverage on Acrivon Therapeutics in a research note on Friday. They issued an “overweight” rating on the stock. Finally, BMO Capital Markets cut their target price on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Acrivon Therapeutics presently has an average rating of “Buy” and a consensus target price of $23.67.

Acrivon Therapeutics Stock Performance

Acrivon Therapeutics stock opened at $6.07 on Friday. Acrivon Therapeutics has a 52-week low of $3.19 and a 52-week high of $11.90. The firm has a 50 day moving average price of $6.34 and a two-hundred day moving average price of $7.34.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new stake in Acrivon Therapeutics in the fourth quarter valued at approximately $40,000. Dimensional Fund Advisors LP acquired a new stake in Acrivon Therapeutics in the 2nd quarter valued at $58,000. Barclays PLC grew its position in Acrivon Therapeutics by 51.2% in the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after purchasing an additional 11,273 shares during the period. JPMorgan Chase & Co. increased its stake in Acrivon Therapeutics by 548.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after purchasing an additional 28,748 shares in the last quarter. Finally, Exome Asset Management LLC acquired a new position in Acrivon Therapeutics during the third quarter worth $817,000. 71.62% of the stock is owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.